<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456803</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-CO-1642</org_study_id>
    <nct_id>NCT04456803</nct_id>
  </id_info>
  <brief_title>Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis</brief_title>
  <official_title>A Study to Evaluate the Efficacy and Safety of Ferric Citrate Tablet for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinomune Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinomune Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of ferric citrate tablet in the control of serum&#xD;
      phosphorus levels in patients with chronic kidney disease undergoing hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, open-label, parallel, phase III study. This study is&#xD;
      consisting of a Screening/Washout period (14 days) and a Treatment/Observation period (12&#xD;
      weeks). The subjects with regular hemodialysis should stop using the phosphorus binder before&#xD;
      the Washout period. During the Treatment period, the subjects will be randomly assigned to&#xD;
      the ferric citrate tablets group (study group) or sevelamer carbonate tablet group (control&#xD;
      group) in the ratio of 1:1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in serum phosphorus levels</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The change in serum phosphorus levels at the end of treatment as compared to baseline (before the first dose).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum phosphorus levels</measure>
    <time_frame>week 2, 4, 6, 8</time_frame>
    <description>Changes in serum phosphorus levels from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of serum phosphorus level</measure>
    <time_frame>week 0, 2, 4, 6, 8, 12</time_frame>
    <description>Area under the curve of serum phosphorus level to visit time (AUC 0-12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects whose serum phosphorus levels reached the target</measure>
    <time_frame>week 4, 6, 8 and 12</time_frame>
    <description>The proportion of subjects whose serum phosphorus levels reached the target range at week 4, 6, 8 and 12 of treatment (the standard was defined as blood phosphorus ≤1.78mmol /L, and ≥1.13mmol /L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in serum calcium (corrected) levels.</measure>
    <time_frame>week 4, 8 and 12</time_frame>
    <description>The change in serum calcium (corrected) levels at week 4, 8 and 12 of treatment as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the level of intact-PTH levels.</measure>
    <time_frame>week 4, 8 and 12</time_frame>
    <description>The change in the level of intact-PTH levels at week 4, 8 and 12 of treatment as compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hyperphosphatemia</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>ESRD</condition>
  <arm_group>
    <arm_group_label>Ferric citrate tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric citrate arm will receive ferric citrate tablets three times a day with each meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevelamer carbonate tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevelamer carbonate arm will receive sevelamer carbonate tablets three times a day with each meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric citrate tablet</intervention_name>
    <description>250mg/tablet, manufactured by Sinomune Pharmaceutical</description>
    <arm_group_label>Ferric citrate tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer carbonate tablet</intervention_name>
    <description>800 mg/tablet, manufactured by Genzyme Ireland Limited</description>
    <arm_group_label>Sevelamer carbonate tablet</arm_group_label>
    <other_name>Renvela</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between the age of 18 and 75 years (including the boundary value) and no gender&#xD;
             limitation;&#xD;
&#xD;
          2. Patients who maintain the hemodialysis schedule (including hemofiltration (HF)&#xD;
             hemodialysis (HDF) hemoperfusion (HP)) as not less than 3 times a week in the 3 months&#xD;
             before random enrollment.&#xD;
&#xD;
          3. Patients with a serum phosphorus level between 1.97 to 3.23 mmol/L (excluding the&#xD;
             boundary value) after washout.&#xD;
&#xD;
          4. Kt/Vurea ≥1.2 or URR ≥65%.&#xD;
&#xD;
          5. Before the screening period, CKD-MBD related drug treatment is stable for more than&#xD;
             one month, including the use of vitamin D (active vitamin D, vitamin D analogues,&#xD;
             etc.) or calcimimetics (cinacalcet, etc.) and the dose remains unchanged.&#xD;
&#xD;
          6. The expected survival is greater than 6 months.&#xD;
&#xD;
          7. Willing to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a serum ferritin level ≥800 ng/mL or TSAT ≥50%.&#xD;
&#xD;
          2. Patients with hemochromatosis or patients receiving treatment for iron overload, or&#xD;
             patients with paroxysmal sleep hemoglobinuria.&#xD;
&#xD;
          3. Patients who received blood transfusions within 3 months prior to Screening, or&#xD;
             patients with hemoglobin ≤60 g/L.&#xD;
&#xD;
          4. Patients with intact-PTH &gt;1000 pg/mL&#xD;
&#xD;
          5. Patients complicated with any of the following gastrointestinal diseases: acute peptic&#xD;
             ulcer, chronic ulcerative colitis, localized enteritis, intestinal obstruction,&#xD;
             habitual constipation (number of stools once per week), and chronic diarrhea (number&#xD;
             of stools four times per day), or patients with a history of gastrectomy or&#xD;
             enterectomy or patients who had undergone gastrointestinal surgery within 3 months&#xD;
             prior to Screening, or patients with dysphagia.&#xD;
&#xD;
          6. Patients with impaired liver function (hepatic dysfunction or serum total bilirubin,&#xD;
             aspartate aminotransferase or alanine aminotransferase ≥ 2 times the upper limit of&#xD;
             normal) or patients with cirrhosis.&#xD;
&#xD;
          7. Patients with a history of parathyroidectomy (PTx) or percutaneous anhydrous ethanol&#xD;
             injection (PEIT) within 6 months.&#xD;
&#xD;
          8. Patients with uncontrolled diabetes or uncontrolled high blood pressure or current&#xD;
             active infectious diseases such as active viral hepatitis.&#xD;
&#xD;
          9. Patients with a history of severe allergies may be allergic to research drugs.&#xD;
&#xD;
         10. Patients with cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.)&#xD;
             or cardiovascular disease (congestive heart failure of Class III or severer in NYHA&#xD;
             classification) requiring hospitalization within 6 months prior to Screening, or&#xD;
             patients who use antiarrhythmic drugs to control arrhythmias or who use antiepileptic&#xD;
             drugs to control seizures.&#xD;
&#xD;
         11. Patients who plan to receive a kidney transplant during the study period.&#xD;
&#xD;
         12. Patients with a history of drug and alcohol abuse&#xD;
&#xD;
         13. Patients with active or advanced malignancy.&#xD;
&#xD;
         14. Women who are pregnant or lactating&#xD;
&#xD;
         15. Patients complicated with active bleeding or requiring anticoagulation therapy with&#xD;
             citrate in hemodialysis&#xD;
&#xD;
         16. Patients who had participated in other clinical studies within 1 month prior to&#xD;
             Screening.&#xD;
&#xD;
         17. Patients who are not suitable for participating in the trial according to the&#xD;
             investigator's judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sinomune Pharma</last_name>
    <phone>+86 18101967192</phone>
    <email>zxh@sinomune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sinomune Pharma</last_name>
    <phone>+86 15951141363</phone>
    <email>huanglu@sinomune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of Baotou medical college</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caili Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guojuan Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuemei Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangcheng Xiao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second hospital of Dalian medical university</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Zheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The affiliated hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianrong Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second people's hospital of Huaian</name>
      <address>
        <city>Huai'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donghui Zheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinan central hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong province Qianfoshan hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zunsong Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bicheng Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The people's hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun Ye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen people's hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinzhou Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The third hospital of Hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiekun Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan provincal people's hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhengzhou People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Xing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhuzhou Central Hospital</name>
      <address>
        <city>Zhuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiumei Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Ürümqi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suhua Li</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

